None ...

In June 2020, Intel announced the first hardware availability of Control-Flow Enforcement Technology (CET). This ...

Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at ...

The 33 companies that made it to this year's Best Fintechs to Work For list are actively preserving remote work options and ...

About Chengdu Origen and Vanotech Chengdu Origen is a clinical-stage gene therapy company focused on developing gene therapy for unmet medical needs and providing meaningful clinical benefits for ...

Chip startup NextSilicon's high-performance-computing-focused accelerators get Sandia National Lab's stamp of approval ...

Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to ...

Chengdu Origen, Vanotech receive US FDA’s IND application clearance of KHN921 to treat hypertrophic cardiomyopathy associated with MYBPC3 mutations: Chengdu, China Saturday, May ...

The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, ...

Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S.

Investigational New Drug application for KHN921 received "study may proceed" from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment o ...

Paul Keating’s warning that Australia risked becoming a “banana republic” if competitiveness did not improve was made 40 ...